Abstract

The purpose of this study was to compare the clinical efficacy of cefotaxime and ceftazidime in preventing infection after percutaneous nephrolithotomy, and to compare the advantages and disadvantages of different cephalosporins antibiotics in the treatment, in order to determine the best preparation. A retrospective controlled trial design was used in this study. A total of 105 patients who underwent percutaneous nephrolithotomy in our hospital from April 2020 to February 2023 were collected, including 47 cases in cefotaxime group and 58 cases in ceftazidime group. The baseline and postoperative infection incidence, blood routine leukocyte level and C-reactive protein level were recorded respectively. Through the follow-up of patients and the collection of related test data, the clinical efficacy and adverse reactions of cefotaxime group and ceftazidime group in preventing infection after percutaneous nephrolithotomy were compared. In this study, postoperative urinary tract infection occurred in 1 case (2.1 %) in cefotaxime group and 3 cases (5.2 %) in ceftazidime group. The total incidence of infection was 2 cases (4.3 %) in cefotaxime group and 8 cases (13.8 %) in ceftazidime group. There was no significant difference between the two groups (purge 0.732). In terms of inflammatory indexes, there was no significant difference in leukocyte level and C-reactive protein level between cefotaxime group and ceftazidime group before treatment. After treatment, the leukocyte level and C-reactive protein level in both groups were significantly lower than those before treatment, and the leukocyte and C-reactive protein levels in cefotaxime group were significantly lower than those in ceftazidime group (p<0.05). This study shows that cefotaxime has certain advantages in preventing infection after percutaneous nephrolithotomy and is helpful to reduce the level of postoperative inflammation.